Use of direct oral anticoagulants for acute pulmonary embolisms in obesity: a propensity-matched, multicentre case-control study

Chinthaka B Samaranayake; Gregory Keir; Simon A A Slader; T Tseng; Khoa Tran; James Anderson; Andrew McCann; Colm McCabe; John W Upham

doi:10.1183/23120541.00379-2021

Use of direct oral anticoagulants for acute pulmonary embolisms in obesity: a propensity-matched, multicentre case-control study

ERJ Open Res. 2021 Aug 31;7(3):00379-2021. doi: 10.1183/23120541.00379-2021. eCollection 2021 Jul.

Authors

Chinthaka B Samaranayake¹, Gregory Keir^{1

2}, Simon A A Slader², T Tseng², Khoa Tran^{1

3}, James Anderson^{4

5}, Andrew McCann², Colm McCabe^{6

7}, John W Upham^{1

2}

Affiliations

¹ Faculty of Medicine, University of Queensland, Brisbane, Australia.
² Princess Alexandra Hospital, Brisbane, Australia.
³ Logan Hospital, Brisbane, Australia.
⁴ Sunshine Coast University Hospital, Birtinya, Australia.
⁵ School of Medicine, Griffith University, Southport, Australia.
⁶ Royal Brompton and Harefield National Health Service Trust, London, UK.
⁷ National Heart and Lung Institute, Imperial College, London, UK.

Abstract

Assessment of efficacy and safety of DOACs in treatment of pulmonary embolisms in obese patients provides reassurance that treatment with DOACs carries similar rates of recurrent VTE and bleeding complications to warfarin https://bit.ly/2VdrSXX.